RxDoctor Payments Data

John Ellena, MD

Internal Medicine · Saint Louis, MONPI 1487767240

Payments from drug & device makers

$10,471in general payments, 2019–2025

Across 685 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$694
  • AstraZeneca$688
  • Novo Nordisk$642
  • GSK$634
  • Boehringer Ingelheim$612
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$10,40299%
  • Education$701%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)132$2,080
Pfizer53$694
AstraZeneca43$688
Novo Nordisk48$642
GSK48$634
Boehringer Ingelheim36$612
Lilly USA, LLC33$479
Johnson & Johnson33$416
Amgen22$392
Novartis20$292
Acadia Pharmaceuticals Inc17$284
E.r. Squibb & Sons, L.L.C.13$209
Merck13$207
Abbott14$203
Currax Pharmaceuticals LLC13$200
Bayer10$183
Azurity Pharmaceuticals, Inc.9$161
Astellas Pharma US Inc9$150
Amarin Pharma, Inc.11$145
Eisai Inc.9$129
Exact Sciences7$126
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$124
Arbor Pharmaceuticals, Inc.9$118
Sanofi Pasteur Inc.6$97
Sumitomo Pharma America, Inc.5$91
Bausch Health US, LLC5$83
Sanofi-aventis U.S. LLC4$63
Kowa Pharmaceuticals America, Inc.4$56
Otsuka America Pharmaceutical, Inc.3$55
Regeneron Healthcare Solutions, Inc.3$55
Biohaven Pharmaceutical Holding Company Ltd.3$48
Baxter Healthcare2$47
Verity Pharmaceuticals Inc.2$43
Insulet Corporation2$40
Ironwood Pharmaceuticals, Inc3$39
Takeda Pharmaceuticals U.S.A., Inc.3$39
Acerus Pharmaceuticals Corporation2$37
Aytu Biopharma, Inc.2$34
Neurocrine Biosciences, Inc.1$33
Corcept Therapeutics1$27
Endo Pharmaceuticals Inc.2$25
Ultragenyx Pharmaceutical Inc.1$23
Supernus Pharmaceuticals, Inc.1$23
Inspire Medical Systems, Inc.1$21
Antares Pharma, Inc.1$21
Heartflow, Inc.1$20
Esperion Therapeutics, Inc.1$20
Mylan Specialty L.p.1$19
Biogen1$19
Ardelyx, Inc.1$19
Phathom Pharmaceuticals, Inc.1$18
Daiichi Sankyo Inc.1$18
Biohaven Pharmaceuticals, Inc.1$17
Scilex Pharmaceuticals Inc.1$17
Sunovion Pharmaceuticals Inc.1$17
Biobeat USA Inc.1$17
Xeris Pharmaceuticals, Inc.1$16
Procept Biorobotics Corporation1$15
Alnylam Pharmaceuticals Inc.1$15
Otsuka Pharmaceutical Development & Commercialization, Inc.1$15

How this compares

$10,471 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$134,405
Medicare patients
258
Services billed
1,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban203$172,555
JardianceEmpagliflozin77$84,894
MounjaroTirzepatide52$62,974
OzempicSemaglutide57$59,454
XareltoRivaroxaban26$25,729
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$19,495
MyrbetriqMirabegron27$19,189
MovantikNaloxegol Oxalate42$17,624
FarxigaDapagliflozin Propanediol14$14,723
LinzessLinaclotide19$11,291
MultaqDronedarone Hcl12$9,419
ArexvyRsvpref3 Antigen/As01e/Pf33$8,695
Breo ElliptaFluticasone/Vilanterol16$8,635
Repatha SyringeEvolocumab16$8,537
GemtesaVibegron12$5,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$694$175,249234 claims
Boehringer IngelheimJardiance$612$84,89477 claims
Lilly USA, LLCMounjaro$479$62,97452 claims
Novo NordiskOzempic$642$59,45457 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta$634$36,82571 claims
Johnson & JohnsonXarelto$416$25,72926 claims
AbbVieLinzess, Restasis, Synthroid$2,080$20,75867 claims
Astellas Pharma US IncMyrbetriq$150$19,18927 claims
AstraZenecaFarxiga, Symbicort$688$18,69831 claims
Sanofi-aventis U.S. LLCMultaq$63$9,41912 claims
Sumitomo Pharma America, Inc.Gemtesa$91$5,85812 claims
MerckBelsomra$207$5,82414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →